Decibel Therapeutics Inc (DBTX) Stock
DBTX is no longer traded. Decibel Therapeutics was delisted from the Nasdaq in September 2023.
Prices on this page are historical; the last trade was September 22, 2023 at $4.91.
Decibel Therapeutics stock price history
DBTX final trading statistics
- Final close
- $4.91
- Final trading day
- Sep 22, 2023
- Market cap at delisting
- $123.37M
- Shares outstanding
- 25.13M
- Final 52-week range
- $1.61 – $5.40
- Avg. volume (final 3 mo.)
- 231,993
- All-time high (split-adj.)
- $19.90 · Feb 2021
- All-time low (split-adj.)
- $1.85 · May 2022
- Return since IPO
- -72.8%
- Beta
- -0.40
- Book value / share
- $2.12
- Price / book
- 2.31
Decibel Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$63.0M | -$2.51 |
| FY2021 | $0.00 | -$51.8M | -$2.64 |
| FY2020 | $0.00 | -$37.6M | -$4.48 |
| FY2019 | $0.00 | -$41.3M | — |
| FY2018 | $0.00 | -$36.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Decibel Therapeutics Inc
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Decibel Therapeutics stock FAQ
What happened to Decibel Therapeutics stock?
Decibel Therapeutics stock was delisted from the Nasdaq. Its final close was $4.91 on September 22, 2023.
Is DBTX stock still trading?
No. DBTX was delisted from the Nasdaq in September 2023 and no longer trades on a U.S. exchange.
What was the last price of DBTX stock?
DBTX closed at $4.91 on its final trading day, September 22, 2023, for a market value of about $123.37M.
What were Decibel Therapeutics's revenue and earnings in its last full fiscal year?
Decibel Therapeutics reported revenue of $0.00 and net income of -$63.0M in fiscal 2022, its last full year as a public company.
When did Decibel Therapeutics go public?
Decibel Therapeutics Inc stock began trading on February 12, 2021.